Claritev Corp

On June 13, 2026, Douglas Garis, Chief Financial Officer, entered into a 10b5-1 sales plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. This 10b5-1 sales plan provides for the sale of (i) up to 40,849 shares of the Company’s Class A common stock related to the vesting of options granted to Mr. Garis and (ii) an indeterminate number of shares of the Company’s Class A common stock related to the vesting of restricted stock units granted to Mr. Garis. The number of shares of the Company’s Class A common stock that will be sold under this 10b5-1 sales plan related to the vesting of restricted stock units is not yet determinable because for each vested restricted stock unit award that is covered by the terms of the plan, an unknown number of shares will be sold to satisfy tax withholding requirements. This 10b5-1 sales plan will become effective on September 21, 2026 and will terminate on December 31, 2026, subject to earlier termination as provided in the plan.

On May 8, 2026, Tiffani Misencik, Chief Growth Officer, entered into a 10b5-1 sales plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. This 10b5-1 sales plan provides for the sale of an indeterminate number of shares of the Company’s Class A common stock related to the vesting of restricted stock units granted to Ms. Misencik. The number of shares of the Company’s Class A common stock that will be sold under this 10b5-1 sales plan is not yet determinable because for each vested restricted stock unit award that is covered by the terms of the plan, an unknown number of shares will be sold to satisfy tax withholding requirements. This 10b5-1 sales plan will become effective on October 15, 2026 and will terminate on November 30, 2026, subject to earlier termination as provided in the plan.